Trial Profile
An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients With Unresectable (Stage IIIc) and Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms CombiRT
- 06 Apr 2022 Status changed from active, no longer recruiting to completed.
- 11 Oct 2020 Planned End Date changed from 30 Jun 2020 to 1 Nov 2020.
- 11 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Nov 2020.